Industry Trends & News
-
Brexit to EU Green Deal: How Europe’s Pharma Rules Are Splitting in Two
read more >>: Brexit to EU Green Deal: How Europe’s Pharma Rules Are Splitting in TwoEurope’s pharmaceutical market is entering a transformative period, with Europe’s Pharma Rules shifting rapidly due to Brexit and the EU Green Deal. As the UK redefines its regulatory identity and the EU tightens sustainability-driven standards, pharma companies must now navigate a divided landscape. Understanding these changes is essential for anyone monitoring EU pharma regulations, assessing…
-
Latin America Pharma Regulations 2026: A Critical Turning Point for Regional Harmonization
read more >>: Latin America Pharma Regulations 2026: A Critical Turning Point for Regional HarmonizationThe landscape of latin america pharma regulations 2026 is entering a pivotal phase. For decades, pharmaceutical companies have operated within a fragmented system, where each country maintains distinct approval pathways, compliance requirements, and pharmacovigilance frameworks. Today, as the latam pharma market 2026 continues to expand, regulatory alignment is no longer optional—it is becoming a strategic…
-
How Diabetes Drug Distribution Just Got 10X More Complex
read more >>: How Diabetes Drug Distribution Just Got 10X More ComplexDiabetes drug distribution used to follow a relatively predictable model. Insulin dominated the biologics segment, oral drugs were handled through conventional wholesale channels, and cold chain requirements were standardized. That model no longer applies the rise of GLP-1 receptor agonists has fundamentally changed diabetes drug logistics. What was once a stable chronic disease distribution system…
-
Semaglutide vs Tirzepatide vs Retatrutide: What Pharma Distributors Need to Know Before Choosing a GLP-1 Product
read more >>: Semaglutide vs Tirzepatide vs Retatrutide: What Pharma Distributors Need to Know Before Choosing a GLP-1 ProductGLP-1 based medications are no longer just another therapeutic category. They have become one of the fastest-moving and most competitive segments in global pharmaceutical distribution. As demand for metabolic weight loss treatments continues to surge, distributors face a practical question: which GLP-1 product makes the most sense to carry, scale, and sustain? Semaglutide, tirzepatide, and…
-
HGH Market Growth Forecast: Industry Outlook Through 2030
read more >>: HGH Market Growth Forecast: Industry Outlook Through 2030The HGH Market is entering a new phase of expansion, with global demand projected to grow steadily through 2030. Driven by advancements in biotechnology, expanding clinical applications, and a rising focus on wellness and anti-aging therapies, the HGH sector—particularly somatropin—continues to attract significant investment. According to industry analysts, the global HGH market size is expected…
-
HGH Market Growth Forecast: Industry Outlook Through 2030
read more >>: HGH Market Growth Forecast: Industry Outlook Through 2030The HGH Market is entering a new phase of expansion, with global demand projected to grow steadily through 2030. Driven by advancements in biotechnology, expanding clinical applications, and a rising focus on wellness and anti-aging therapies, the HGH sector—particularly somatropin—continues to attract significant investment. According to industry analysts, the global HGH market size is expected…
-
Tirzepatide Market Size 2025: Projections, Growth Drivers, and Key Players
read more >>: Tirzepatide Market Size 2025: Projections, Growth Drivers, and Key PlayersTirzepatide market has emerged as one of the most transformative drugs in the global pharmaceutical market, redefining the treatment landscape for both type 2 diabetes and obesity. As a dual GIP and GLP-1 receptor agonist, it delivers superior efficacy in weight reduction and blood glucose management compared to earlier-generation therapies. With rapidly increasing demand, expanding…
-
GDP 2025: The Overlooked Warehouse Rule That’s Causing 80% of Audit Failures
read more >>: GDP 2025: The Overlooked Warehouse Rule That’s Causing 80% of Audit FailuresA silent crisis is unfolding in pharma logistics: 80% of recent Good Distribution Practice (GDP) audit failures trace back to one overlooked 2025 update—and most warehouses are dangerously unprepared. The culprit? EU GDP 2025’s new Chapter 9.2, which mandates:🔴 Real-time temperature monitoring (no more data loggers alone)🔴 Blockchain-based custody trails for high-risk shipments🔴 Automated deviation…
-
Global Serialization Countdown: Which Countries Are Enforcing Laws in 2025?
read more >>: Global Serialization Countdown: Which Countries Are Enforcing Laws in 2025?The world is entering the most aggressive phase of pharmaceutical serialization enforcement yet. By December 2025, 87% of global drug markets will have active serialization laws—and non-compliant companies face product seizures, steep fines, and even criminal penalties. This isn’t just about barcodes anymore. 2025 marks the tipping point where serialization becomes the universal language of…